Literature DB >> 12922119

Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.

William D Pratt1, Nancy L Davis, Robert E Johnston, Jonathan F Smith.   

Abstract

The central objective of this research was to test molecularly defined, live attenuated Venezuelan equine encephalitis virus (VEEV) vaccine candidates that were produced through precise genetic manipulation of rationally selected viral nucleotide sequences. Molecular clones of vaccine candidates were constructed by inserting either three independently attenuating mutations or a PE2 cleavage-signal mutation with a second-site resuscitating mutation into full-length cDNA clones. Vaccine candidate viruses were recovered through DNA transcription and RNA transfection of cultured cells, and assessed in rodent and non-human primate models. Based on results from this assessment, one of the PE2 cleavage-signal mutants, V3526, was determined to be the best vaccine candidate for further evaluation for human use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922119     DOI: 10.1016/s0264-410x(03)00328-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

1.  Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Authors:  Michael D Parker; Marilyn J Buckley; Vanessa R Melanson; Pamela J Glass; David Norwood; Mary Kate Hart
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.

Authors:  Svetlana Atasheva; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

3.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

4.  Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Authors:  Ann R Hunt; Richard A Bowen; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  Virology       Date:  2011-04-13       Impact factor: 3.616

Review 5.  Encephalitic alphaviruses.

Authors:  Michele A Zacks; Slobodan Paessler
Journal:  Vet Microbiol       Date:  2009-08-28       Impact factor: 3.293

6.  A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).

Authors:  Donald L Fine; Erin Jenkins; Shannon S Martin; Pamela Glass; Michael D Parker; Brad Grimm
Journal:  J Virol Methods       Date:  2009-11-10       Impact factor: 2.014

Review 7.  Vaccines for Venezuelan equine encephalitis.

Authors:  Slobodan Paessler; Scott C Weaver
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Douglas S Reed; Jessica L Price; Craig A Koeller; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

9.  IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice.

Authors:  Shannan L Rossi; Mathilde Guerbois; Rodion Gorchakov; Kenneth S Plante; Naomi L Forrester; Scott C Weaver
Journal:  Virology       Date:  2013-01-22       Impact factor: 3.616

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.